Sign inCreate account

Report workspace tools

NCT02879305COMPLETEDanonymous

A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Erythropoietin-stimulating Agents

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

Phase 3

Modality

AI-normalized

small molecule

Target

AI-normalized

Anemia in Chronic Kidney Disease

Indication / condition

AI-normalized

Anaemia

Intervention

Source record

Daprodustat, rhEPO, Placebo, Iron therapy

Source & freshness

Source record

NCT ID

NCT02879305

Original source

ClinicalTrials.gov

Source last updated

Dec 03, 2021

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02879305

Title

A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Erythropoietin-stimulating Agents

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

Phase 3

Condition raw

Anaemia

Condition normalized

Anaemia

Modality raw

Anaemia

Modality normalized

small molecule

Target raw

Anemia in Chronic Kidney Disease

Target normalized

Anemia in Chronic Kidney Disease

Interventions

Daprodustat, rhEPO, Placebo, Iron therapy

Public preview

Source record

The ASCEND-D trial evaluated the safety and efficacy of daprodustat, a novel prolyl hydroxylase inhibitor, in treating anemia associated with chronic kidney disease (CKD) in dialysis patients. Conducted by GlaxoSmithKline, the study involved 2,964 participants across 431 centers in 35 countries, comparing daprodustat to recombinant human erythropoietin (rhEPO).

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Erythropoietin-stimulating Agents

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02879305

Status

COMPLETED

Phase

Phase 3

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

The ASCEND-D trial evaluated the safety and efficacy of daprodustat, a novel prolyl hydroxylase inhibitor, in treating anemia associated with chronic kidney disease (CKD) in dialysis patients. Conducted by GlaxoSmithKline, the study involved 2,964 participants across 431 centers in 35 countries, comparing daprodustat to recombinant human erythropoietin (rhEPO).

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedDec 03, 2021
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02879305

Indication

Anaemia

Modality

small molecule

Target

Anemia in Chronic Kidney Disease

Intervention

Daprodustat, rhEPO, Placebo, Iron therapy

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.